PE20000559A1 - Formulacion de tabletas comprimidas de efavirenz - Google Patents

Formulacion de tabletas comprimidas de efavirenz

Info

Publication number
PE20000559A1
PE20000559A1 PE1999000431A PE00043199A PE20000559A1 PE 20000559 A1 PE20000559 A1 PE 20000559A1 PE 1999000431 A PE1999000431 A PE 1999000431A PE 00043199 A PE00043199 A PE 00043199A PE 20000559 A1 PE20000559 A1 PE 20000559A1
Authority
PE
Peru
Prior art keywords
efavirenz
formulation
compressed tablets
aids
inhibitor
Prior art date
Application number
PE1999000431A
Other languages
English (en)
Inventor
Udit Batra
Raymond J Higgins
Karen C Thompson
Ashok V Katdare
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9815800.9A external-priority patent/GB9815800D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of PE20000559A1 publication Critical patent/PE20000559A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Abstract

SE REFIERE A UNA FORMULACION DE TABLETAS COMPRIMIDAS QUE COMPRENDE a)50% EN PESO DE EFAVIRENZ, b)COMPONENTE DE CARGA TAL COMO LACTOSA, CARBONATO DE CALCIO, SULFATO DE CALCIO, ENTRE OTROS; c)DESINTEGRANTE Y SUPERDESINTEGRANTE TALES COMO ACIDO ALGINICO, CARBOXIMETILCELULOSA SODICA, DIOXIDO DE SILICIO COLOIDAL, CROSCARMELOSA, ENTRE OTROS; d)AGLUTINANTE TAL COMO ACACIA, ACIDO ALGINICO, CARBOMERO, HIDROXIPROPILCELULOSA, ENTRE OTROS; e)SURFACTANTE TAL COMO DOCUSATO DE SODIO, CLORURO DE BENZALCONIO, CLORURO DE BENCETONIO Y CETRIMIDA f)COMPONENTE DE CARGA/COADYUVANTE DE COMPRESION TAL COMO CARBONATO DE CALCIO, SULFATO DE CALCIO, AZUCARES COMPRESIBLES, LACTOSA HIDRATADA SECADA POR ATOMIZACION, ENTRE OTROS; g)LUBRICANTE TAL COMO ESTEARATO DE CALCIO, MONOESTEARATO DE GLICERILO, PALMITOESTEARATO DE GLICERILO, ACEITE DE RICINO MINERAL, ENTRE OTROS Y i)SOLVENTE TAL COMO AGUA, ETANOL. UNA COMPOSICION PREFERIDA CONTIENE 300mg DE EFAVIRENZ, 120mg DE CELULOSA MICROCRISTALINA, 19,2mg DE HIDROXIPROPILCELULOSA, 30mg DE CROSCARMELOSA SODICA, 6mg DE SULFATO LAURICO Y SODIO, 118,8mg DE LACTOSA HIDRATADA SECADA POR ATOMIZACION, 6mg DE ESTEARATO DE MAGNESIO. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL EFAVIRENZ ES UN INHIBIDOR DE TRANSCRIPTASA INVERSA NO NUCLEOSIDO Y PUEDE SER UTIL PARA EL TRATAMIENTO DE INFECCIONES POR VIH Y SIDA
PE1999000431A 1998-05-27 1999-05-21 Formulacion de tabletas comprimidas de efavirenz PE20000559A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8692198P 1998-05-27 1998-05-27
GBGB9815800.9A GB9815800D0 (en) 1998-07-21 1998-07-21 Compressed tablet formulation

Publications (1)

Publication Number Publication Date
PE20000559A1 true PE20000559A1 (es) 2000-07-05

Family

ID=26314071

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000431A PE20000559A1 (es) 1998-05-27 1999-05-21 Formulacion de tabletas comprimidas de efavirenz

Country Status (14)

Country Link
EP (1) EP1083901B1 (es)
JP (1) JP4000354B2 (es)
AT (1) ATE237332T1 (es)
AU (1) AU761182B2 (es)
CA (1) CA2332876C (es)
CO (1) CO5070643A1 (es)
CY (1) CY1113191T1 (es)
DE (1) DE69906963D1 (es)
DK (1) DK1332757T3 (es)
ES (1) ES2388849T3 (es)
PE (1) PE20000559A1 (es)
PT (1) PT1332757E (es)
SI (1) SI1332757T1 (es)
WO (1) WO1999061026A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72207C2 (uk) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
WO2003045327A2 (en) * 2001-11-27 2003-06-05 Bristol-Myers Squibb Company Efavirenz tablet formulation having unique biopharmaceutical characteristics
CN101965974A (zh) 2002-07-24 2011-02-09 儿童医院医疗中心 含有对映体牛尿酚的组合物和产物及其用途
EP1923063A3 (en) 2003-01-14 2009-04-08 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
US7198653B2 (en) * 2003-07-31 2007-04-03 Delavau Llc Calcium carbonate granulation
JP2005089396A (ja) * 2003-09-19 2005-04-07 Pola Chem Ind Inc イソフラボン含有経口投与組成物
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
EP1906937B1 (en) 2005-07-22 2016-10-19 Rubicon Research Pvt Ltd. Novel dispersible tablet composition
WO2007013047A2 (en) * 2005-07-29 2007-02-01 Ranbaxy Laboratories Limited Water-dispersible anti-retroviral pharmaceutical compositions
UA95093C2 (uk) * 2005-12-07 2011-07-11 Нікомед Фарма Ас Спосіб одержання кальцієвмісної сполуки
WO2009026257A2 (en) * 2007-08-17 2009-02-26 Teva Pharmaceutical Industries Ltd. Methods and compositions for controlling the bioavailability of poorly soluble drugs
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
CN102985072A (zh) 2010-04-20 2013-03-20 希普拉有限公司 药物组合物
MX339570B (es) * 2010-05-11 2016-05-31 Janssen Pharmaceutica Nv Formulaciones farmaceuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienil-metilbenceno como inhibidores de transportadores de glucosa dependientes de sodio.
EP2447255A1 (en) 2010-10-14 2012-05-02 Lonza Ltd. Process for the synthesis of cyclic carbamates
EP2441759A1 (en) 2010-10-14 2012-04-18 Lonza Ltd. Process for the synthesis of cyclic carbamates
PT2753306T (pt) * 2011-10-17 2020-11-11 Lexicon Pharmaceuticals Inc Formas de dosagem sólidas de 2-amino-3-(4-(2-amino-6-((r)-1- (4-cloro-2-(3-metil-1h-pirazol-1-il)fenil)-2,2,2- trifluoroetoxi)pirimidin-4-il)fenil)propanoato de (s)-etilo
CN103508973B (zh) * 2012-06-25 2016-04-27 上海迪赛诺药业有限公司 制备依非韦伦i型结晶的方法
WO2015059466A1 (en) 2013-10-25 2015-04-30 Cipla Limited Pharmaceutical compositions comprising efavirenz
RU2759544C1 (ru) * 2021-01-29 2021-11-15 Общество с ограниченной ответственностью "АМЕДАРТ" Твёрдая фармацевтическая композиция для изготовления перорального терапевтического средства для профилактики и/или лечения ВИЧ-инфекции
CN113499441A (zh) * 2021-08-05 2021-10-15 上海合全医药有限公司 一种药用糖包衣液及其制备方法
CN113999543B (zh) * 2021-10-29 2022-11-04 广西华纳新材料股份有限公司 一种钙-硅核壳结构纳米碳酸钙的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020389A1 (en) * 1994-01-28 1995-08-03 Merck & Co., Inc. Benzoxazinones as inhibitors of hiv reverse transcriptase
US5633405A (en) * 1995-05-25 1997-05-27 Merck & Co., Inc. Asymmetric synthesis of (-)-6-chloro-4-cyclopropyl-ethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxanzin-2-one
BR9809127A (pt) * 1997-05-17 2000-08-01 Glaxo Group Ltd Combinação, formulação farmacêutica, processo para o tratamento de uma infecção por hiv em um animal infectado, uso de (-) -(1s,4r)-4-[2-amino-6-(ciclopropil amino)-9h-purin-9-il)-2-ciclopenteno-1-metanol, e, pacote de paciente

Also Published As

Publication number Publication date
CA2332876A1 (en) 1999-12-02
PT1332757E (pt) 2012-09-03
ATE237332T1 (de) 2003-05-15
WO1999061026A1 (en) 1999-12-02
EP1083901A1 (en) 2001-03-21
SI1332757T1 (sl) 2012-10-30
AU761182B2 (en) 2003-05-29
DK1332757T3 (da) 2012-09-24
EP1083901B1 (en) 2003-04-16
DE69906963D1 (de) 2003-05-22
JP4000354B2 (ja) 2007-10-31
AU4201099A (en) 1999-12-13
JP2002516281A (ja) 2002-06-04
CY1113191T1 (el) 2016-04-13
CO5070643A1 (es) 2001-08-28
CA2332876C (en) 2008-07-08
ES2388849T3 (es) 2012-10-19

Similar Documents

Publication Publication Date Title
PE20000559A1 (es) Formulacion de tabletas comprimidas de efavirenz
HUP0101598A2 (hu) Aszpartil proteáz inhibitorok prodrugjai és ezeket tartalmazó gyógyszerkészítmények
BR9908438A (pt) Tabletes de desintegração rápida
MY136173A (en) 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
EP1268412B8 (en) Sulphonamido-substituted bridged bicycloalkyl derivatives
AU2003297260A1 (en) Fast-disintegrating solid dosage forms being not friable and comprising pullulan
HK1049103A1 (zh) 含有利托那韋(abt-538)並與茚地那韋(mk-639)結合藥物的組合物以及他們在治療艾滋病中的用途
MX339071B (es) Almidon pregelatinizado en una formulacion de liberacion controlada.
BG106030A (en) Pharmaceutical composition
EE03805B1 (et) Peroraalselt manustatava farmatseutilise kompositsiooni kasutamine meeste erektiilse talitlushäire raviks ettenähtud ravimi valmistamiseks
WO2004030611A3 (en) Non-nucleoside reverse transcriptase inhibitors
HUP0102206A2 (hu) Delavirdint tartalmazó tabletta formájú készítmény
HUP0401569A2 (hu) Amlodipint és atorvastatint tartalmazó gyógyászati készítmények és eljárás az előállításukra
HUP0400553A2 (hu) Gyógyászati készítmények
DE59813162D1 (de) Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektionen
ID28510A (id) Formulasi oral yang baru untuk agonis atau antagonis 5-ht4
HUP0004544A2 (hu) Angiotenzin-átalakító enzim inhibitora és diuretikum kombinációjának alkalmazása mikrokeringési rendellenességek kezelésére szolgáló gyógyászati készítmény előállítására
IL132853A (en) Composition for modulating the human sexual response
NO960775L (no) Anvendelse av kinoksaliner i kombinasjon med proteaseinhibitorer som legemiddel for behandling av AIDS og/eller HIV-infeksjoner
BR0209155A (pt) Tablete farmacêutico tendo um teor de api elevado
HUP9901353A2 (hu) ACE-inhibitorok alkalmazása diszpepsziás tünetek kezelésére alkalmas gyógyszerkészítmény előállítására
SE0001916D0 (sv) Novel formulation
ECSP013979A (es) Formulación de tabletas de oxazolidinona
MY121604A (en) Combination therapy for hiv infection using the hiv protease inhibitor indinavir and the reverse transcriptase inhibitor 3tc together with azt
AR011707A1 (es) Composicion farmaceutica que comprende tirosina y un alergeno opcionalmente modificado, procedimiento para su preparacion y el uso de la misma para la manufactura de un medicamento.

Legal Events

Date Code Title Description
FG Grant, registration
MK Expiration of term